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ly appropriate lesions in patients with or without suffi-
cient pulmonary compromise, such that the use of pneu-
monectomy is contraindicated.
The operative risks of sleeve resection are similar to
those of pneumonectomy,1 and sleeve resection provides
no apparent advantage for long-term survival. Thus the
oncologic advantage of sleeve resection over pneu-
monectomy in patients with sufficient pulmonary
reserve is unclear. Impaired function and shortened
long-term survival because of the impact of cardiopul-
monary compromise have been cited among the consid-
erations that have prompted the decreased use of pneu-
monectomy in favor of sleeve resection.2 To determine
the impact of pneumonectomy on long-term survival, we
reviewed our experience with pneumonectomy in the
treatment of lung cancer and analyzed its influence on
survival compared with that of standard lobar resection.
Methods
We retrospectively reviewed the cases of patients with ini-
tial primary lung cancer who underwent major lung resection
at The University of Chicago Hospitals between January 1980
T he appropriate extent of parenchymal resection inthe treatment of lung cancer remains controversial.
For decades pneumonectomy has been the operation of
choice for central or locally advanced tumors. During
the past two decades there has been a growing experi-
ence with the use of parenchyma-sparing techniques
such as sleeve lobectomy in the management of this
subgroup of cancers. The indications for the use of such
procedures are not well defined but include anatomical-
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and June 1998. The patient treatment methods and techniques
of data collection have been described previously.3 Patient
evaluation included a history and physical examination, pos-
teroanterior and lateral chest radiographs, and blood tests
including a complete blood cell count and serum chemistry
evaluations. Computed tomographic (CT) scans of the chest
and upper abdomen (including the liver and adrenal glands)
were done routinely beginning in 1983. Brain CT scans and
bone scintiscans were done in cases of bone pain or those
with neurologic symptoms or signs and routinely in patients
with T3 primary tumors or with stage IIIA or more advanced
cancers. Pulmonary function tests including a calculation of
single-breath diffusing capacity for carbon monoxide were
done routinely. All patients had a preoperative or intraopera-
tive bronchoscopic examination. Cervical mediastinoscopy or
parasternal mediastinotomy were routinely done in patients
with pathologically enlarged mediastinal lymph nodes on the
CT scan and in patients with suspected T3 disease and were
also done in selected other patients.
All patients were treated according to the prevailing proto-
cols at the time of presentation. Patients with clinical stage I
and stage II non–small cell lung cancers underwent thoraco-
tomy, lung resection, and mediastinal nodal sampling as pri-
mary therapy, and the latter group normally received postop-
erative radiotherapy and chemotherapy. Some patients with
stage IIIA or IIIB lung cancer, so classified on the basis of
mediastinal nodal involvement, were treated with preopera-
tive radiation therapy and chemotherapy in conjunction with
lung resection. Other patients with stage IIIA lung cancer on
the basis of the presence of T3 primary lung cancer without
apparent lymph node enlargement were treated by surgical
resection initially. Patients with N2 disease discovered at
operation had postoperative adjuvant chemotherapy and
radiotherapy. All cancers were staged at a weekly chest
oncology conference on the basis of the final pathologic diag-
nosis with use of the American Joint Committee for Cancer
Staging staging system.4
Operative complications were classified as pulmonary
(postoperative mechanical ventilation for > 24 hours or rein-
tubation for ventilatory support after the day of the operation;
pneumonia defined as fever, leukocytosis, and pulmonary
infiltrate necessitating antibiotic therapy; air leak from thora-
costomy tubes for more than 7 days after the operation; and
lobar collapse on postoperative chest radiograph), cardiovas-
cular (new requirements for β-blockers, calcium channel
inhibitors, or vasodilating agents; the need for postoperative
inotropic support other than renal dose dopamine; pulmonary
embolism; myocardial infarction; and arrhythmia), other
(wound infection, empyema, recurrent nerve injury, bron-
chopleural fistula, and other miscellaneous conditions), and
death. Operative mortality was defined as death during hospi-
talization for lung resection or any death within 30 days of the
operation.
Follow-up was done through periodic clinic visits until the
patient’s death. In some patients annual contact with the treat-
ing physician and/or the patient was done through our insti-
tutional cancer registry. Follow-up was complete (to death or
to within 1 year of analysis in survivors) in 384 (87%) of 442
patients: 291 (86%) of 340 patients undergoing lobectomy/
bilobectomy and 93 (91%) of 102 patients undergoing pneu-
monectomy (P = .14).
Cases were evaluated for demographic, surgical, and
pathologic variables, and the distributions of these variables
were compared between types of operations with the χ2 test
for discrete variables and the Student t test for continuous
variables (see Table I). The risk of operative mortality was
analyzed initially by univariate analysis. Variables that had a
P value <.15 were further evaluated with the use of back-
wards elimination, multivariable, logistic regression analysis.
Survival was measured from the date of operation and sur-
vivorship calculated according to the Kaplan-Meier method.5
Confidence intervals (CI) for median survival time were cal-
culated as described by Brookmeyer and Crowley.6 Differ-
ences in survival between groups were tested for significance
by the log-rank test.7 A Cox proportional hazards model was
fit to examine and adjust for the effects of surgical treatment
and other covariates on survival.8 Because there were a num-
ber of missing values for some variables, the Cox propor-
tional hazards models were re-fit imputing operative-group
specific mean values for the missing variables. All analyses
were done with either the Minitab 10.51 (Minitab, Inc, State
College, Pa) or Systat 8.0 (SPSS, Inc, Chicago, Ill) programs.
Data are expressed as mean ± SD.
Results
Major lung resections were done in 442 patients with
non–small cell lung cancer. There were 259 men and
183 women with a mean age of 62.6 ± 10.4 years (range
35-87 years). Patients undergoing pneumonectomy
were younger, had a lower serum albumin concentra-
tion, a lower forced vital capacity expressed as a percent
of predicted, a lower forced expiratory volume in 1 sec-
ond expressed as a percent of predicted (FEV1%), and a
higher incidence of preoperative radiotherapy than
patients who underwent lobectomy or bilobectomy
(Table I). Pneumonectomy was done more often for
squamous cell cancer than for other histologic types
(Table II). Patients undergoing pneumonectomy had
more advanced T stage, N stage, and overall stage than
did those undergoing lobectomy/bilobectomy.
The perioperative pulmonary complication rate was
higher for patients undergoing lobectomy/bilobectomy
(101/339; 30% [95% CI 25%-35%]) than for those
undergoing pneumonectomy (16/101; 16% [9%-23%];
P = .005), largely because of the incidence of persistent
air leak in the former group. In contrast, the cardiovas-
cular complication rate was higher for patients under-
going pneumonectomy (29/96; 30% [21%-39%]), pri-
marily because of a higher incidence of arrhythmias
than in the lobectomy/bilobectomy group (69/325;
21% [17%-26%]; P = .041).
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The overall operative mortality was 36 of 442 (8.1%
[5.6%-11%]) and was higher in the pneumonectomy
group (12/102; 12% [5.5%-18%]) than in the lobecto-
my/bilobectomy group (24/340; 7.0% [4.3%-9.7%]),
but the difference did not reach statistical significance
(P = .13). Multivariable logistic regression analysis
revealed preoperative hypertension and single-breath
diffusing capacity expressed as a percent of predicted
(DLCO%) to be the best determinants of operative
mortality, with odds ratios of 2.6 (1.3-5.2) for hyper-
tension and 1.1 (1.0-1.2) for a 10-point decrease in
DLCO%. The mortality rate decreased from 8.8% dur-
Table I. Clinical characteristics of patients undergoing major resection for non–small cell lung cancer
All patients Lobectomy/bilobectomy Pneumonectomy P value
Age (y) 62.6 ± 10.0 (442) 63.1 ± 10.2 (340) 60.8 ± 9.1 (102) .027
Men 259/442; 59% 191/340; 56% 68/102; 67% .059
Smoking history 419/441; 95% 324/339; 96% 95/102; 93% .3
Diabetes 58/442; 13% 50/340; 15% 8/102; 8% .072
Hypertension 140/440; 32% 115/340; 34% 25/100; 25% .096
Prior MI 50/437; 11% 40/338; 12% 10/99; 10% .6
Preoperative radiotherapy 30/347; 9% 16/277; 6% 14/70; 20% <.001
Preoperative chemotherapy 9/339; 3% 7/266; 3% 2/64; 3% .8
Performance status 9.2 ± 1.5 (430) 9.2 ± 1.5 (332) 9.4 ± 1.3 (98) .2
Serum creatinine (mg/dL) 1.11 ± 0.98 (263) 1.14 ± 1.08 (216) 1.02 ± 0.27 (47) .14
Serum hemoglobin (gm/dL) 13.1 ± 1.6 (273) 13.2 ± 1.6 (227) 12.9 ± 1.9 (46) .3
Serum albumin (gm/dL) 4.00 ± 0.48 (349) 4.04 ± 0.48 (266) 3.87 ± 0.46 (83) .005
PO2 (mm Hg) 78.2 ± 11.3 (352) 78.4 ± 11.5 (268) 77.4 ± 10.9 (84) .4
PCO2 (mm Hg) 38.0 ± 4.2 (352) 38.1 ± 4.1 (268) 37.6 ± 4.5 (84) .3
FVC (L) 3.22 ± 0.89 (432) 3.25 ± 0.91 (334) 3.10 ± 0.82 (98) .12
FVC% 86.6 ± 17.9 (407) 88.2 ± 17.9 (324) 80.4 ± 16.6 (83) <.001
FEV1 (L) 2.22 ± 0.70 (432) 2.24 ± 0.73 (334) 2.15 ± 0.58 (98) .2
FEV1% 83.0 ± 21.0 (407) 84.3 ± 21.6 (324) 78.0 ± 17.7 (83) .007
DLCO% 86.2 ± 22.0 (366) 85.4 ± 20.9 (291) 89.3 ± 25.7 (75) .2
Numbers in parentheses indicate the number of patients for whom data were available. Performance status was graded on a scale of 10 to 1. MI, Myocardial infarc-
tion; FVC, forced vital capacity; FVC%, forced vital capacity expressed as a percent of predicted; DLCO%, diffusing capacity of carbon monoxide expressed as a
percent of predicted.
Table II. Histologic type and pathologic staging in patients undergoing major resection for non–small cell lung
cancer
All patients (442) Lobectomy/bilobectomy (340) Pneumonectomy (102) P value
Histology <.001
Squamous cell 200 (45%) 128 (38%) 72 (71%)
Adenocarcinoma 196 (44%) 173 (51%) 23 (23%)
Other 46 (11%) 39 (12%) 7 (7%)
T stage <.001
1 143 (33%) 131 (39%) 12 (12%)
2 204 (47%) 151 (45%) 53 (54%)
3 73 (17%) 48 (14%) 25 (25%)
4 17 (4%) 8 (2%) 9 (9%)
Unknown 5 2 3
N stage <.001
0 247 (57%) 221 (65%) 26 (26%)
1 98 (22%) 59 (17%) 39 (39%)
2, 3 92 (21%) 58 (17%) 34 (34%)
Unknown 5 2 3 
Stage <.001
I 206 (47%) 194 (57%) 12 (12%)
II 101 (23%) 60 (18%) 41 (41%)
III 124 (28%) 77 (23%) 47 (47%)
IV 10 (2%) 9 (3%) 1 (1%)
Unknown 1 0 1
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ing the period 1980 to 1989 to 7.5% during the period
1990 to 1998 (P = .6). The mortality rates for lobecto-
my/bilobectomy during these periods did not change
(10/166 or 6.0% [2.4%-9.6%] vs 14/173 or 8.1%
[4.0%-12%]; P = .5), whereas the mortality rate
decreased substantially for pneumonectomy (11/74 or
15% [6.9%-23%] vs 1/28 or 3.6% [0%-10%]; P = .14).
The relative rate of pneumonectomy decreased
between the two periods (74/240 or 31% [25%-37%] vs
28/201 or 14% [9.1%-19%]; P < .001).
The mean follow-up interval was 40.5 ± 45.9 months.
Overall median and 5-year survivals for lobectomy/
bilobectomy were significantly greater than those for
pneumonectomy (Table III; Fig 1). Median and 5-year
survivals were related to pathologic stage and histolog-
ic type (Table III; Fig 2). Cox proportional hazards esti-
mation of survival using the covariates histologic type
(classified as squamous cell carcinoma, adenocarcino-
ma, or other), age, sex, hypertension, preoperative radi-
ation therapy, performance status, serum albumin con-
centration, FEV1%, year of operation, type of
operation, primary tumor (T) status, and regional node
(N) status (stages I, II, and III only) demonstrated T sta-
tus, N status, age, performance status, and FEV1% to be
statistically significant covariates, whereas the type of
operation did not achieve significance after adjusting
for these variables (Table IV). An analysis done that
examined only operative survivors also demonstrated T
status, N status, age, performance status, and FEV1% to
be significant covariates, whereas the type of operation
did not achieve significance (Table IV). These analyses
excluded patients with missing data. However, reanaly-
ses using the imputed values demonstrated no signifi-
cant effect of type of operation on survival (hazard
ratios of 1.02 [0.73-1.42] and 1.19 [0.84-1.69] for all
patients and for operative survivors, respectively).
Because survival among patients with stage I disease
was more favorable for the patients undergoing pneu-
monectomy, potentially skewing the analysis of an
operation typically done to treat regionally advanced
disease, additional analyses were done with only data
from patients with stage II or III disease. Using the
same covariates listed previously, Cox proportional
hazards estimation of survival demonstrated T status, N
status, age, and FEV1% to be statistically significant
risk factors, whereas the type of operation did not
achieve statistical significance (Table V). An analysis
restricted to operative survivors also demonstrated T
status, N status, age, and FEV1% to be significant
covariates, whereas the type of operation again did not
achieve significance (Table V). Reanalyses using the
imputed values yielded no significant effect of type of
operation on survival (hazard ratios of 1.07 [0.76-1.51]
and 1.07 [0.74-1.56] for all patients and for operative
survivors, respectively).
Discussion
The appropriate extent of parenchymal resection for
the treatment of lung cancer is determined by tumor
location, tumor stage, pulmonary reserve, and a variety
of other factors including patient age and performance
status. Although the use of pneumonectomy to treat
centrally located or regionally advanced lung cancers is
standard for patients with adequate pulmonary reserve,
the use of sleeve resection techniques for selected
patients from this population is growing. The advan-
tages of parenchyma-sparing techniques for patients
with limited pulmonary reserve are obvious, and reports
have documented that the spared parenchyma functions
appropriately.2,9 However, the risk of complications
specific to parenchyma-sparing procedures is not trivial
and includes a local recurrence rate of 10%, benign
strictures or stenoses in 5% of patients, and bronchial
fistula formation in 6% of patients.1 Considering these
risks, the relative advantages of parenchyma-sparing
operations in patients with sufficient pulmonary reserve
to permit pneumonectomy are unclear.
Early reports suggested that pneumonectomy was
Fig 1. Kaplan-Meier survival curves for patients undergoing
lobectomy/bilobectomy or pneumonectomy, all stages com-
bined (P < .001 by log-rank). Vertical bars indicate standard
error. Numbers at bottom indicate patients at risk at yearly
intervals for lobectomy/bilobectomy (top number) and pneu-
monectomy (bottom number).
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associated with important long-term consequences that
affected quality of life and possibly long-term survival.
These consequences included decreased diffusing
capacity and elevated pressures in the right side of the
heart during exercise in most patients and progression
of emphysema and the development of pulmonary
hypertension resulting in cor pulmonale in some
patients.10 More recent research has confirmed these
observations while providing a sound physiologic basis
for the findings.11 Clinical experience with pneu-
monectomy during the past several decades, in con-
junction with improved methods of patient selection
for major lung resection, has reduced operative mortal-
ity and morbidity. Nevertheless, concern persists
regarding the long-term consequences of pneumonec-
tomy. The current analysis was done to determine
Fig 2. Kaplan-Meier survival curves for patients undergoing lobectomy/bilobectomy or pneumonectomy classi-
fied according to pathologic stage. The log-rank test was used to compare curves within each stage. Vertical bars
indicate standard error. Numbers at bottom indicate patients at risk at yearly intervals for lobectomy/bilobectomy
(top number) and pneumonectomy (bottom number).
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whether pneumonectomy is an independent factor
affecting long-term survival after surgical treatment for
lung cancer.
Our patient population and operative outcomes were
similar to those of most academic medical centers. The
operative mortality rate, although in line with rates
reported by others,12-14 was somewhat higher than in
most centers.15-17 Interestingly, although the mortality
for pneumonectomy decreased somewhat from the first
to the second decade covered in our analysis, a similar
change was not evident among patients who had lobec-
tomy or bilobectomy. The reasons for this are not clear,
but the findings may be related to local referral patterns
to tertiary care centers.
We found the long-term survival for patients under-
going pneumonectomy to be significantly shorter than
that for those undergoing lobectomy/bilobectomy, con-
firming findings of previous reports based on univariate
analyses.18,19 However, the multivariable analysis
demonstrated that the type of operation was not a sig-
nificant independent determinant of long-term survival,
as has been suggested by others.20,21 Important covari-
ates for long-term survival included patient age, preop-
erative spirometry, and T and N status. Age has been
Table III. Median and 5-year survival after major resection for non–small cell lung cancer
All patients Lobectomy/bilobectomy Pneumonectomy
Median (mo) Five-year (%) Median (mo) Five-year (%) Median (mo) Five-year (%) P value*
Stage
I 75 (55-101) 56 (48-64) 73 (48-101) 55 (47-63) N/A N/A .19
II 28 (21-39) 32 (22-42) 36 (26-51) 35 (21-49) 18 (11-25) 26 (11-41) .05
III 18 (14-22) 20 (12-28) 21 (17-27) 18 (8-27) 12 (9-16) 21 (9-33) .07
Histology
Squamous cell 27 (23-35) 33 (26-40) 32 (26-41) 33 (24-42) 19 (11-27) 30 (19-42) .068
Adenocarcinoma 36 (29-64) 43 (35-51) 46 (34-79) 46 (38-55) 14 (9-19) 18 (2-34) <.001
Other cell types 74 (31-N/A) 54 (35-74) 92 (31-N/A) 58 (35-80) 20 (6-N/A) N/A .3
All patients 34 (27-41) 39 (34-44) 38 (34-51) 43 (36-49) 17 (12-21) 30 (20-40) <.001
Numbers in parentheses indicate 95% CI; not available (N/A) represents values that have not yet been reached or are not calculable.
*Lobectomy/bilobectomy vs pneumonectomy (log rank test).
Table IV. Hazard ratios for covariates of survival
after resection for non–small cell lung cancer
Hazard ratio 95% CI P value
All patients (n = 429)
T2 vs T1 1.36 1.00-1.85 .051
T3, 4 vs T1 1.72 1.19-2.48 .004
N1 vs N0 1.97 1.44-2.70 <.001
N2, 3 vs N0 2.48 1.81-3.40 <.001
Age* 1.35 1.18-1.55 <.001
Performance status† 1.26 1.07-1.49 .006
FEV1%‡ 1.06 1.03-1.10 .001
Operation§ 1.12 0.83-1.50 .45
Operative survivors (n = 396)
T2 vs T1 1.30 0.94-1.81 .11
T3, 4 vs T1 1.69 1.14-2.49 .009
N1 vs N0 2.10 1.50-2.94 <.001
N2, 3 vs N0 2.84 2.03-3.96 <.001
Age 1.35 1.16-1.57 <.001
Performance status 1.24 1.03-1.49 .022
FEV1% 1.07 1.03-1.11 .001
Operation 1.10 0.80-1.51 .56
*Age: 10-year increase.
†Performance status: 3-point decrease.
‡FEV1%: 10-point decrease.
§Operation: pneumonectomy rather than lobectomy/bilobectomy.
Table V. Hazard ratios for covariates of survival after
resection for non–small cell lung cancer for patients
with regionally advanced (stages II, III) disease
Hazard ratio 95% CI P value
All patients (n = 223)
T2 vs T1 1.69 1.02-2.81 .043
T3, 4 vs T1 2.31 1.32-4.03 .003
N1 vs N0 2.38 1.36-4.18 .003
N2, 3 vs N0 2.87 1.60-5.14 <.001
Age* 1.22 1.02-1.46 .025
FEV1%† 1.07 1.02-1.13 .005
Operation‡ 1.21 0.88-1.68 .24
Operative survivors (n = 204)
T2 vs T1 1.70 1.00-2.89 .05
T3, 4 vs T1 2.25 1.25-4.05 .007
N1 vs N0 2.29 1.26-4.17 .007
N2, 3 vs N0 2.98 1.60-5.55 .001
Age 1.24 1.03-1.50 .025
FEV1% 1.08 1.03-1.14 .003
Operation 1.15 0.81-1.62 .44
*Age: 10-year increase.
†FEV1%: 10-point decrease.
‡Operation: pneumonectomy rather than lobectomy/bilobectomy.
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identified previously as a determinant of long-term sur-
vival after major lung resection.22,23
The finding that preoperative spirometry is a predic-
tor of long-term survival after major resection for lung
cancer has not been widely reported. That survival is
unfavorably influenced at the low extremes of spiro-
metric measurements in populations with chronic
obstructive pulmonary disease is well known.24,25
Recent experience with lung volume reduction opera-
tions for end-stage emphysema has confirmed these
findings.26 Our results extend the evidence for a rela-
tionship between spirometry and long-term survival to
include patients with less marked impairments in air
flow. The effect of spirometry on long-term survival is
relatively small compared with the effects of patholog-
ic stage and age. Nevertheless, further investigation of
this relationship is warranted.
Our results suggest that pneumonectomy can be done
with acceptable incidences of operative morbidity and
mortality and that this extent of resection does not have
an important effect on long-term survival. However, the
CIs were wide and therefore larger studies are needed.
Moreover, despite adjustment for observed covariates,
the effects of patient selection and other potential con-
founding factors limit the conclusions that can be
drawn from this retrospective study, suggesting that
randomized prospective trials would be needed to
definitively address this issue.
These findings must not be taken to suggest that the
use of pneumonectomy should be widely expanded in
patients undergoing resection to treat lung cancer.
Judicious assessment of the appropriate extent of oper-
ation remains a vital element in the surgical manage-
ment of lung cancer. Complete resection remains the
hallmark of a successful operation. An important area
of controversy is the appropriate management of cen-
trally located cancers in patients with sufficient pul-
monary reserve to permit pneumonectomy. The selec-
tion of a lesser resection such as sleeve lobectomy in
such patients might expose them to an increased risk of
local recurrence. In such instances, if there is doubt
about the completeness of resection, pneumonectomy
should be considered.
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Discussion
Dr Joel D. Cooper (St Louis, Mo). It is always a bit
provocative when something is presented that seems to be a
little counterintuitive. I think it was Warren Buffett who said
he never invests in anything that he does not understand.
Before I buy into the conclusions, I need to understand it a bit
more.
You cite a significant risk for sleeve lobectomy but point
out that the risk is similar to that for pneumonectomy, and I
think in most series it is, usually in the 5% range. However, I
do think that the risk of sleeve lobectomy is not greater than
that of pneumonectomy and that the risk of local recurrence
in selected patients is not greater, so intuitively one would
think that doing a lesser resection would be advantageous.
How often did you use sleeve resection in your overall
group of resections during this period? I have always used a
benchmark that 5% to 8% of all pulmonary resections should
probably be sleeve resections, on the basis of reviewing a
number of series, so I am curious to know whether you did or
did not have a bias for sleeve resection and how widely you
employed it.
You looked at death, but clearly quality of life and func-
tional outcome would be important factors in evaluating the
difference between lobe and lung resection. Do you have any
information on functional outcome or performance data for
the patients who did have a lung removed versus those who
had a lesser resection?
I am not much of a statistician, and I guess I even have a
certain amount of suspicion, but I am a little puzzled. In the
manuscript, you did show that stage for stage and cell type for
cell type the pneumonectomy survival is much less; both
median survival and 5-year survival are less than in the group
that had a lesser resection. Is it possible that pneumonectomy
really is a significant risk factor but that there is a type 2 error
here, namely, that the analysis just did not have enough sta-
tistical power to demonstrate that pneumonectomy is a risk
factor? Maybe some insight into that could be gained by look-
ing at how many of the deaths were attributable to malignant
disease recurrence versus other causes of death. Is there a dis-
crepancy in the death rate from strokes, heart attacks, respira-
tory failure, and other cardiopulmonary conditions between
the two groups that might suggest that pneumonectomy real-
ly does have an inherent risk factor?
Finally, you acknowledged a fairly high incidence of death
after pneumonectomy in the first part of the series that reduced
very significantly in the second half of the series, I think from
15% down to 3% or 4%. Was that a response to the high mor-
tality in the first half of the series? In the latter part of your
series, do you think that there were patients who did not get an
operation at all but who could have had a sleeve resection
because of the concern regarding the risk of pneumonectomy?
Dr Ferguson. Those are all excellent questions. I think I
would take a little different stance on the risk of local recur-
rence after sleeve lobectomy versus more standard opera-
tions. A recent meta-analysis of sleeve resection versus more
standard resections clearly showed that there is a substantial
risk, perhaps about 10%, for local recurrence compared with
that in more standard resections. Thus the question is, what is
the advantage of sleeve resection over more standard opera-
tions, and you have to argue that it is quality of life, presum-
ably because of preservation of pulmonary parenchyma.
Whether that permits the patient to live longer or whether that
provides more of an area for a new lung cancer to develop
may be controversial. How those balance out is unknown.
You mentioned that you use 5% to 8% of the total number
of lung resections as a baseline figure for sleeve lobectomy:
our incidence is probably lower than that, more in the range of
1% to 2%. Because this report covers such a number of years
and a wide variety of surgeons, it is difficult to say why that is
the case. We are using it in our armamentarium, certainly now,
as a standard operation for very specific indications.
I think that quality of life is a very important issue. The
information presented here looks only at raw survival.
Unfortunately, we have no data regarding quality of life, and
I think that needs to be looked into.
The statistics are interesting and challenging. One of the
things that we did early on was always to stratify according
to stage when we were doing our multivariable analyses. In
the initial analysis, patients with stage I disease appeared to
do better. We discarded those data and reanalyzed stages II
and III alone. We found that some of the effects of the type of
operation became apparent when it was looked at that way.
One of the issues is that bundling patients into these broad
stage categories tends to obscure the effects of the TNM clas-
sifications. Therefore, rather than stratifying for stage, we
separated the patients according to T status and N status,
which then eliminated much of the effect of the type of oper-
ation in the analysis.
I do not have accurate information regarding cause of
death. Our tumor registry categorizes patients according to
death from tumor, death from other causes, and unknown,
and just looking at those data, it did not appear that there was
much difference in the long-term death rate because of recur-
rent cancer, but whether there is an increased death rate
because of cardiopulmonary complications in the pneu-
monectomy group is not possible to say in our database.
In terms of the selection of patients for pneumonectomy,
you probably noticed that the frequency of pneumonectomy
did decrease during the second decade of the study. I think
this probably did have something to do with patient selection.
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It is conceivable that some patients were denied an operation
because of our caution. I do not think it was based necessar-
ily on our perceived high percentage of mortality because we
had not really analyzed those data, but maybe it was more of
a gut feeling to be a little bit more conservative about the
operations.
Dr Malcolm M. DeCamp (Cleveland, Ohio). When you
looked at all the different confounding variables, and there
are some cases of higher stage disease in the analysis, did you
think that the use of adjuvant/neoadjuvant therapy was pretty
evenly distributed in the groups of both pneumonectomies
and lobectomies for stages II and III disease? Obviously this
is going to have an impact on survival as the outcome.
Is it possible that part of the reason the type of operation
did not appear statistically significant was that, as you noted,
the mortality in the lobectomy group was a little higher than
you might predict, certainly in contemporary series? Given
that the patients undergoing lobectomy did worse than
expected and the patients undergoing pneumonectomy did a
little bit better, perhaps you washed out the statistical signif-
icance when you looked at the type of operation as a risk fac-
tor affecting long-term survival.
Dr Ferguson. We looked at neoadjuvant chemotherapy
and neoadjuvant radiation therapy. There were too few
patients, only about 30, who had neoadjuvant chemotherapy
to enter into the analysis. We did use neoadjuvant radiation
therapy as one of the variables in the multivariable analysis,
and that fell out very early as a predictor of long-term mor-
tality. We have not had an opportunity to look at postopera-
tive adjuvant therapy of either type and whether that affects
long-term survival.
We repeated the analysis excluding operative mortality
because of the concern that you raised about the differential
operative mortality possibly confounding the outcome. The
results were identical regardless of whether we included or
excluded patients with operative mortality.
Dr Douglas J. Mathisen (Boston, Mass). You imply that
there may be some advantage conferred by pneumonectomy
relative to local recurrence, and maybe you cannot get that
information from your tumor registry, but do you have any
sense of whether local recurrence was affected by pneu-
monectomy compared with lobectomy?
Dr Ferguson. No, I am sorry. I do not have the informa-
tion, and I have not generated a sense about it either.
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